Fairvalue-Calculator Fairvalue-Calculator
EN DE

OnKure Therapeutics, Inc (OKUR) Fair Value & Analysis

Healthcare · US · Market cap $181M

Price$4.20
Fair Value$6.26
Upside+49.0%
Quality91/100
Evidence: Low Range $4.69 – $7.82

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

OnKure Therapeutics, Inc (OKUR) currently trades at $4.20, while our model-based Fair Value estimate is $6.26 — implying the stock looks roughly 49.0% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is OnKure Therapeutics, Inc (OKUR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $6.26 versus a price of $4.20 — about +49% (undervalued). Model-based estimate, not financial advice.
What is the fair value of OKUR?
Our 21-model fair value for OnKure Therapeutics, Inc is $6.26 (as of Jun 24, 2026), built from audited fundamentals. The current price is $4.20.
What is the quality score of OKUR?
OnKure Therapeutics, Inc has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.